TCGA-97-7547-01A-11R-2039-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.350
- ANDROGEN_RESPONSE+0.310
- ESTROGEN_RESPONSE_EARLY+0.310
- PEROXISOME+0.300
- HEDGEHOG_SIGNALING+0.290
- UV_RESPONSE_DN+0.280
- HEME_METABOLISM+0.230
- BILE_ACID_METABOLISM+0.220
- TGF_BETA_SIGNALING+0.220
- ADIPOGENESIS+0.210
Top 10 suppressed
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V1-0.470
- MYC_TARGETS_V2-0.470
- DNA_REPAIR-0.360
- SPERMATOGENESIS-0.300
- INTERFERON_ALPHA_RESPONSE-0.290
- MTORC1_SIGNALING-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- OXIDATIVE_PHOSPHORYLATION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-6146-01A-11R-1755-07 | — | cohortA1 | 0.851 |
| 2 | TCGA-75-6206-01A-11R-1755-07 | — | cohortA2 | 0.848 |
| 3 | BS_CGB2WS2A | pilocytic astrocytoma | — | 0.842 |
| 4 | SRR8518290 | — | F | 0.837 |
| 5 | TCGA-78-7162-01A-21R-2066-07 | — | cohortA2 | 0.836 |
| 6 | TCGA-62-8395-01A-11R-2326-07 | — | cohortA2 | 0.833 |
| 7 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.802 |
| 8 | SRR8613737 | — | F | 0.801 |
| 9 | C3L-03679 | — | cohortA1 | 0.800 |
| 10 | TCGA-05-4384-01A-01R-1755-07 | — | cohortA2 | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |